Search
First randomized evidence for kinase inhibitor activity in acute myeloid leukemia
Despite the success of tyrosine kinase inhibitors in some forms of leukemias such as chronic myeloid leukemia and acute lymphoblastic leukemia, until now a kinase inhibitor had yet to demonstrate activity in acute myeloid leukemia (AML).
Read moreEvaluation of a single 1.000 mg iron dose as ferric carboxymaltose (FCM) for fatigue treatment in Iron deficient women – PREFER
Fatigue and iron deficiency are prevalent among women of childbearing age. This randomised, placebo-controlled study evaluated the effect of a single intravenous 1.
Read morePublications
Overall Survival With Daratumumab, Bortezomib, and Dexamethasone in Previously Treated Multiple Myeloma (CASTOR): A Randomized, Open-Label, Phase III Trial
P. Sonneveld, A. Chanan-Khan, K. Weisel, A. K. Nooka, T. Masszi, M. Beksac, I. Spicka, V. Hungria, M. Munder, M.
SWG Educational Activities
MeetingsEHA SWG EWALL SymposiumLocation and dateThis meeting was held in Frankfurt in June 2023 as part of EHA2023. TopicPersonalized ALL therapy. ChairNicola Gokbuget
Sessions and speakers
B-cell precursor ALL, the Finnish experience (Kimmo Porkka).
SWG Educational Activities
2023 meetingsThe following EHA-SWG meetings took place in the past calendar year:
54th General Assembly of ERIC members at ELN Symposium 2023
Mannheim, Germany
April 18, 2023
ERIC/Brazilian CLL Group workshop on biomarkers in CLL
Brasilia, Brazil
May 25–26, 2023
55th General Assembly of ERIC members at…
Highlights of the EHA-EMA Joint Symposium on RWE
The fourth EHA-EMA Joint Symposium at EHA2024 brought together investigators, regulators and patients to discuss the use of real world evidence (RWE) in the evaluation of new drugs.
Read more“Complement-ing” positive outcomes during the COVID-19 pandemic
Dr Dimitrios Mastellos (@dmastellos)
The COVID-19 pandemic has had a huge impact on research worldwide. Multiple projects have been halted and researchers have lost their jobs.
SWG Educational Activities
EHA-SWG meetingsAn EMSCO meeting was held in October 2023 (Nice, France).
Read moreIbrutinib improves survival in CLL and SLL patients: Results From the RESONATE Study.
Patients with chronic lymphoid leukemia (CLL) or small lymphocytic lymphoma (SLL) who experience short response duration or adverse cytogenetics have poor outcomes.
- 1
- 2
- 3
- 4
- 5
- 6
- 7
- 8
- 9
- 10
- 11
- 12
- 13
- 14
- 15
- 16
- 17
- 18
- 19
- 20
- 21
- 22
- 23
- 24
- 25
- 26
- 27
- 28
- 29
- 30
- 31
- 32
- 33
- 34
- 35
- 36
- 37
- 38
- 39
- 40
- 41
- 42
- 43
- 44
- 45
- 46
- 47
- 48
- 49
- 50
- 51
- 52
- 53
- 54
- 55
- 56
- 57
- 58
- 59
- 60
- 61
- 62
- 63
- 64
- 65
- 66
- 67
- 68
- 69
- 70
- 71
- 72
- 73
- 74
- 75
- 76
- 77
- 78
- 79
- 80
- 81
- 82
- 83
- 84
- 85
- 86
- 87
- 88
- 89
- 90
- 91
- 92
- 93
- 94
- 95
- 96
- 97
- 98
- 99
- 100
- 101
- 102
- 103
- 104
- 105
- 106
- 107
- 108
- 109
- 110
- 111
- 112
- 113
- 114
- 115
- 116
- 117
- 118
- 119
- 120
- 121
- 122
- 123
- 124
- 125
- 126
- 127
- 128
- 129
- 130
- 131
- 132
- 133
- 134
- 135
- 136
- 137
- 138
- 139
- 140
- 141
- 142
- 143
- 144
- 145
- 146
- 147
- 148
- 149
- »